Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of proprietary drugs to treat central nervous system disorders, including schizophrenia, bipolar disorder, and other mental health conditions. The company is known for its innovative therapies and has a portfolio that includes products addressing underserved patient populations. Founded in 2000 and headquartered in Washington, D.C., Vanda emphasizes research and development to bring new treatment options to market.
Company News
Vanda Pharmaceuticals reported a Q2 2025 net loss of $27.2 million, with revenue rising 4% to $52.6 million. Fanapt® showed strong sales growth, while HETLIOZ® and PONVORY® experienced declines. The company continues to invest in its product pipeline and expand market reach.
The schizophrenia market is growing due to increased R&D activities, advancements in neurobiology and biomarkers, and ongoing clinical trials for more effective treatments. This has attracted significant investments and led to the development of innovative therapies, including novel antipsychotics and personalized medicine.
Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Wednesday. The Dow traded up 0.04% to 37,813.77 while the NASDAQ fell 0.78% to 15,742.21. The S&P 500 also fell, dropping, 0.34% to 5,034.17. Check This Out: Alphabet, Toll Brothers And 2 Other Stocks Insiders Are Selling  Leading and...